Combination Chemotherapy Consisting of Pegylated Liposomal Doxorubicin and Carboplatin in Malignant Gynecologic Tumours
Pegylated Liposomal Doxorubicin as well as Carboplatin have been showed efficacy in monotherapy as in combination therapy of gynaecologic tumours. As there is no common standard in the therapy of recurrent ovarian carcinoma, tumours of the uterus nor for non-epithelial ovarian tumours at time of designing of this study, this trial shall evaluate the new and well tolerated combination therapy consisting of Pegylated Liposomal Doxorubicin and Carboplatin.
Cancer of the Ovary Treated as 2nd Line Therapy|Muellerian Mixed Tumours|Tumours of the Uterus|Cervical Cancers|Non-Epithelial Ovarian Tumours
DRUG: Pegylated Liposomal Doxorubicin and Carboplatin
Tolerance|Response Rate mainly in malignant uterine tumours
Time to Progression mainly in malignant uterine tumours|Overall Survival mainly in malignant uterine tumours
Aim of these study is the evaluation of combination chemotherapy in a patient subset with gynecologic tumours on regard to tolerance and efficacy.